tirzepatide head to head semaglutide SURPASS-2 (NEJM 2021) was the definitive head-to-head: vs 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions transitioning from semaglutide to tirzepatide

Table of Contents Retatrutide and Diarrhoea: What the Evidence Shows Phase 2 trial data confirm diarrhoea is a common adverse effect of retatrutide, driven largely by its GLP-1 receptor agonist component, which slows gastric emptying and alters intestinal transit

The most commonly reported side effects of semaglutide include gastrointestinal issues, such as nausea, vomiting, diarrhea and constipation

Comfort : The perfect choice for needle haters

This means less degradation, less first-pass metabolism, and a far more direct route to the bloodstream

If you are experiencing injection site reactions at a given dose, extending that period to 6 or 8 weeks before escalating gives your body additional time to develop tolerance